Glucose-insulin-potassium therapy in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
| Autor: | Qin-Fu Han, Hai-San Zhang, Xiao-Yan Guo, Wei-Fang Liang, Pei-Yin Jin |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome Time Factors Subgroup analysis Drug Administration Schedule law.invention Time-to-Treatment Randomized controlled trial law Risk Factors Internal medicine medicine Odds Ratio Humans Insulin Infusions Parenteral Hospital Mortality Glucose–insulin–potassium Cardioplegic Solutions Randomized Controlled Trials as Topic Chi-Square Distribution business.industry Odds ratio medicine.disease Confidence interval Surgery Cardiac surgery Heart Arrest Meta-analysis Glucose Treatment Outcome Potassium business Cardiology and Cardiovascular Medicine Chi-squared distribution Research Article |
| Zdroj: | BMC Cardiovascular Disorders |
| ISSN: | 1471-2261 |
| Popis: | Background Glucose-insulin-potassium (GIK) has been advocated in the setting of acute coronary syndrome (ACS) to reduce ischemia-related arrhythmias and myocardial injury. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess whether the use of GIK infusions >3 or 3 hours after the onset of symptoms, on mortality and/or cardiac arrest. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for each outcome. Results Nine trials were identified and eligible for review. The summary OR for in-hospital mortality was 1.01 (95% CI 0.94 to 1.09), based on 2,542 deaths among 27,294 patients. The subgroup analysis according to the study enrollment time (within 3 hours [OR, 0.77, 95% CI 0.50-1.16], vs. >3 hours [OR, 0.90; 95% CI, 0.67-1.21]) did not reveal any difference in mortality. Conclusions Administration of GIK in ACS patients does not significantly reduce mortality whether or not GIK administration >3 or |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink